摘要
射血分数保留的心力衰竭(HFpEF)是一种在病理生理学和临床表现等方面异质性较高的综合征,随着人口老龄化,高血压、心房颤动、糖尿病、慢性肺部疾病等疾病的增多,HFpEF的患病率也在持续升高。但由于其机制表现的复杂性和异质性,传统的心力衰竭治疗药物对HFpEF相关的研究并未显示出有明显的益处,临床研究屡屡受挫,治疗上仍少有突破进展,当前越来越强调针对发病机制来进行精准治疗,其病理生理学、诊断标准和临床治疗仍存在争议,现作一综述。
Heart failure with preserved ejection fraction(HFpEF)is a syndrome that is highly heterogeneous in terms of pathophysiology and clinical manifestations,and the prevalence of HFpEF is increasing with the ageing of the population and the increase in hypertension,atrial fibrillation,diabetes and chronic lung diseases.However,due to the complexity and heterogeneity of the mechanism of presentation,traditional heart failure treatment drugs have not shown significant benefit in studies related to HFpEF,and clinical studies have been repeatedly frustrated,with few breakthroughs in the treatment.There is an increasing emphasis on precision therapy targeting the pathogenesis,and the pathophysiology,diagnostic criteria and clinical treatment are still controversial,and are reviewed here.
作者
孙晓凤
曹邦明
SUN Xiaofeng;CAO Bangming(Binzhou Medical Universify,Yantai 264003,Shandong,P.R.China;Yantai Affiliated Hospital of Binzhou Medical University,Yantai 264100,Shandong,P.R.China)
出处
《滨州医学院学报》
2021年第6期466-469,472,共5页
Journal of Binzhou Medical University
基金
滨州医学院科研计划(BY2018KYQD14)
滨州医学院“临床医学+X”学位点培育建设项目(内科学-心血管病学)
山东省中医药科技发展计划(2019-05-09)
烟台市科技计划(2019YD065)。
关键词
射血分数保留的心力衰竭
发病机制
诊断
治疗
heart failure with preserved ejection fraction
pathogenesis
diagnosis
treatment